{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-085138","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.620288+00:00","generated_at":"2026-05-19T11:33:01.208774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"enGene Q2 loss $25.8M ($0.51/shr); cash $251.5M; LEGEND study on track","bullets":["Net loss $25.8M ($0.51/shr) vs $15.0M ($0.38) YoY; operating expenses $27.1M (up 57%).","Cash and marketable securities $251.5M expected to fund operations into 2027.","LEGEND pivotal cohort enrollment on track; BLA filing for detalimogene planned mid-2026.","EMA indicates data could support Conditional Marketing Authorization for BCG-unresponsive NMIBC.","Amy Pott appointed Chief Global Commercialization Officer effective May 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-085138","json":"https://secwatch.observer/filing/0000950170-25-085138.json","markdown":"https://secwatch.observer/filing/0000950170-25-085138.md","text":"https://secwatch.observer/filing/0000950170-25-085138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025085138/0000950170-25-085138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025085138/engn-20250612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T11:33:01.208774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}